Health related quality of life among HIV-HCV co-infected patients;La qualité de vie des patients co-infectés par le VIH et le VHC

Revue d'Epidemiologie et de Sante Publique

Volumn 54, Issue HS1, 2006, Pages

  Preau M ^a,b,e   Protopopescu, C ^a   Spire, B ^a,e   Dellamonica, P ^c,e   Poizot Martin, I ^d,e   Villes, V ^a,e   Carrieri, M P ^a,e   Boirot, C ^e   Bouhnik, A D ^e   Cassuto, J P ^e   Chesney, M ^e   Dujardin, P ^e   Gallais, H ^e   Gastaut, J A ^e   Lepeu, G ^e   Marimoutou, C ^e   Mechali, D ^e   Moatti, J P ^e   Moreau, J ^e   Negre M ^e   Obadia, Y ^e   Pradier, C ^e   Rey, D ^e   Rouzioux, C ^e   Sobel, A ^e   Tremolieres F ^e   Vlahov, D ^e   more..

^a OBSERVATOIRE RÉGIONAL DE LA SANTÉ PROVENCE ALPES CÔTE D AZUR   (France)

^b University of Aix Marseille   (France)

^c CENTRE HOSPITALIER UNIVERSITAIRE DE NICE   (France)

^d HÔPITAL SAINTE MARGUERITE   (France)

^e NONE

Author keywords

Drug maintenance treatment; Health related quality of life; HIV HCV positive; Injecting drug users; Injection status

Indexed keywords

ANTIRETROVIRUS AGENT;

ADULT; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; COPING BEHAVIOR; DEPRESSION; DISEASE COURSE; DRUG DEPENDENCE TREATMENT; DRUG WITHDRAWAL; FEMALE; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTRAVENOUS DRUG ABUSE; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MENTAL HEALTH; QUALITY OF LIFE; QUESTIONNAIRE; SELF REPORT; SOCIAL SUPPORT; SUPERINFECTION; TREATMENT OUTCOME;

ADULT; ANTI-RETROVIRAL AGENTS; BUPRENORPHINE; COHORT STUDIES; COUNSELING; DATA INTERPRETATION, STATISTICAL; DEPRESSION; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HEPATITIS C; HIV INFECTIONS; HIV SEROPOSITIVITY; HIV-1; HUMANS; MALE; METHADONE; NARCOTIC ANTAGONISTS; NARCOTICS; QUALITY OF LIFE; QUESTIONNAIRES; SOCIAL SUPPORT; SOCIOECONOMIC FACTORS; SUBSTANCE ABUSE, INTRAVENOUS; TIME FACTORS;

EID: 33746900747     PISSN: 03987620     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. Rosenbrock R, Dubois-Arber F, Moers M, Pinell P, Schaeffer D, Setbon M The normalization of AIDS in Western European countries. Social Science and Medicine 2000; 50: 1607-29.
2. Setbon M. La normalisation paradoxale du sida. Revue Française de Sociologie 2000; 41: 61-78.
3. Sabin CA. The changing clinical epidemiology of AIDS in the highly active antiretroviral therapy era. Aids 2002; 16 (Suppl 4): : S61-8.
4. CASCADE T, Collaboration. Survival after introduction of HAART in people with known duration of HIV-1 infection. Lancet 2000; 355: 1158-9.
5. Mocroft A, Vella S, Benfield TL, Chiesi A, Miller V, Gargalianos P, et al. Changing patterns of mortality across Europe in patients infected with HIV-1. Euro-SIDA Study Group. Lancet 1998; 352: 1725-30.
6. Allardice GM, McMenamin JJ, Parpia T, Gibbs J, McSharry C, Whitelaw J. The recent impact of antiretroviral combination therapy on CD4 counts, AIDS and death in HIV-infected persons: routine HIV surveillance in Scotland. Int J STD AIDS 1998; 9: 561-6.
7. Allen LL, Haririfar M, Cohen J, Henderson MJ. Quality of life and locus of control of migraineurs. Clin Excell Nurse Pract 2000; 4: 41-9.
8. Morin M . Parcours de santé. Paris: Armand Colin; 2004.
9. World Health Organization. Report of the Working Group on Concepts and Principles of Health Promotion. Copenhagen: WHO; 1984.
10. Jasmin C. Cancer et sida : des modèles pour l'étude de la qualité de vie. In: Jasmin C, J ay, A., Bez, G., editor. Cancer, Sida La qualité de vie. Paris: Synthélabo Groupe, Les empêcheurs de penser en rond, 1996: 17-22.
11. Préau M. Evaluation psychosociale de la qualité de vie des patients infectés par le VIH. Aix en Provence: Université de Provence Aix Marseille I, 2004.
12. Dalgard O, Egeland A, Skaug K, Vilimas K, St een T. Health-related quality of life in active injecting drug users with and without chronic hepatitis C virus infection. Hepatology 2004; 39: 74-80.
13. Shor-Posner G, Lecusay R, Miguez-Burbano MJ, Quesada J, Rodriguez A, Ruiz P, et al. Quality of life measures in the Miami HIV-1 infected drug abusers cohort: relationship to gender and disease status. J Subst Abuse 2000; 11: 395-404.
14. Moore RD, Keruly JC, Chaisson RE. Differences in HIV disease progression by injecting drug use in HIV-infected persons in care. J Acquir Immune Defic Syndr 2004; 35: 46-51.
15. McNaghten AD, Hanson DL, Dworkin MS, Jones JL. Differences in prescription of antiretroviral therapy in a large cohort of HIV-infected patients. J Acquir Immune Defic Syndr 2003; 32: 499-505.
16. Carrieri MP, Moatti JP, Vlahov D, Obadia Y, Reynaud-Maurupt C, Chesney M. Access to antiretroviral treatment among French HIV infected injection drug users: the influence of continued drug use. MANIF 2000 Study Group. J Epidemiol Community Health 1999; 53: 4-8.
17. Giacomuzzi SM, Riemer Y, Ertl M, Kemmler G, Rossler H, Hinterhuber H, et al. Buprenorphine versus methadone maintenance treatment in an ambulant setting: a health-related quality of life assessment. Addiction 2003; 98: 693-702.
18. Moatti JP, Carrieri MP, Spire B, Gastaut JA, Cassuto JP, Moreau J. Adherence to HAART in French HIV-infected injecting drug users: the contribution of buprenorphine drug maintenance treatment. The MANIF 2000 study group. AIDS 2000; 14: 151-5.
19. Bouhnik AD, Préau M, Vincent E, Carrieri MP, Gallais H, Lepeu G, et al. Depression and clinical progression in HIV-infected drug users treated with highly active antiretroviral therapy. Antivir Ther 2005; 10: 53-61.
20. Gandek B, Ware JE, Jr., Aaronson NK, Alonso J, Apolone G, Bjorner J, et al. Tests of data quality, scaling assumptions, and reliability of the SF-36 in eleven countries: results from the IQOLA Project. International Quality of Life Assessment. J Clin Epidemiol 1998; 51: 1149-58.
21. Fuhrer R, Rouillon F. La version française de l'échelle CES-D. Description and translation of the autoevaluation scale (in French). Psychiatrie et Psychobiologie 1989; 4: 163-6.
22. Radloff L. The CES-D scale: a self-report depression scale for research in the general population. Applied Psychology Measurement 1977; 3: 385-491.
23. Lyketsos CG, Hoover DR, Guccione M, Senterfitt W, Dew MA, Wesch J, et al. Depressive symptoms as predictors of medical outcomes in HIV infection. Multicenter AIDS Cohort Study. JAMA 1993; 270: 2563-7.
24. Burack JH, Barrett DC, Stall RD, Chesney MA, Ekstrand ML, Coates TJ. Depressive symptoms and CD4 lymphocyte decline among HIV-infected men. JAMA 1993; 270: 2568-73.
25. White JM. Pleasure into pain: the consequences of long-term opioid use. Addict Behav 2004; 29: 1311-24.
26. Smith J. Beyond the divide between cognition and discourse: using interpretative phenomenological analysis in health psychology. Psychology and Health 1998; 11: 261-71.
27. Greenfield L, Bigelow GE, Brooner RK. Validity of intravenous drug abusers' self-reported changes in HIV high-risk drug use behaviors. Drug Alcohol Depend 1995; 39: 91-8.
28. Latkin CA, Vlahov D. Socially desirable response tendency as a correlate of accuracy of self-reported HIV serostatus for HIV seropositive injection drug users. Addiction 1998; 93: 1191-7.
29. Darke S. Self-report among injecting drug users: a review. Drug Alcohol Depend 1998; 51: 253-63 (discussion 67-8).
30. Messiah A, Loundou AD, Maslin V, Lacarelle B, Moatti JP. Physician recognition of active drug use in HIV-infected patients is lower than validity of patient's self-reported drug use. J Pain Symptom Manage 2001; 21: 103-12.
31. Muni R, Fantoni M, Del Borgo C, Visona R, Barracco A, Zambelli A, et al. Determinants of health-related quality of life in HIV-infected patients. AIDS Care 2003; 15: 581-90.
32. Hays RD, Cunningham WE, Sherbourne CD, Wilson IB, Wu AW, Cleary PD, et al. Health-related quality of life in patients with human immunodeficiency virus infection in the United States: results from the HIV Cost and Services Utilization Study. Am J Med 2000; 108: 714-22.
33. Hudson A, Kirksey K, Holzemer W. The influence of symptoms on quality of life among HIV-infected women. West Journal of Nursing Research 2004; 26: 9-23 (discussion 4-30).
34. Carrieri MP, Spire B, Duran S, Katlama C, Peyramond D, Francois C, et al. Health-related quality of life after 1 year of highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2003; 32: 38-47.
35. Préau M, Leport C, Salmon-Ceron D, Carrieri P, Portier H, Chene G, et al. Health-related quality of life and patient-provider relationships in HIV-infected patients during the first three years after starting PI-containing antiretroviral treatment. AIDS Care 2004; 16: 651-63.
36. Préau M, Vincent E, Spire B, Reliquet V, Fournier I, Michelet C, et al. Health-related quality of life and health locus of control beliefs among HIV-infected treated patients. J Psychosom Res 2005: 59; 407-13.
37. Jia H, Uphold CR, Wu S, Reid K, Findley K, Duncan PW. Health-related quality of life among men with HIV infection: effects of social support, coping, and depression. AIDS Patient Care STDs 2004; 18: 594-603.
38. Ciesla JA, Roberts JE. Meta-analysis of the relationship between HIV infection and risk for depressive disorders. Am J Psychiatry 2001; 158: 725-30.
39. Johnson JG, Rabkin JG, Lipsitz JD, Williams JB, Remien RH. Recurrent major depressive disorder among human immunodeficiency virus (HIV)-positive and HIV-negative intravenous drug users: findings of a 3-year longitudinal study. Compr Psychiatry 1999; 40: 31-4.
40. Marimoutou C, Carrieri P, Poizot-Martin I, Loundou A, Tremolieres F, Rey D, et al. Hospitalization for depressive syndrome in a cohort of HIV-infected patients contaminated through injecting drug use: MANIF 2000 cohort, France, 1995-1999. AIDS Care 2003; 15: 729-34.
41. Burgoyne R, Renwick R. Social support and quality of life over time among adults living with HIV in the HAART era. Social Science and Medicine 2004; 58: 1353-66.
42. Fraenkel L, McGraw S, Wongcharatrawee S, Garcia-Tsao G. Patients' experiences related to anti-viral treatment for hepatitis C. Patient Educ Couns 2005 Aug 9.
43. Penedo FJ, Gonzalez JS, Dahn JR, Antoni M, Malow R, Costa P, et al. Personality, quality of life and HAART adherence among men and women living with HIV/AIDS. J Psychosom Res 2003; 54: 271-8.
44. Grangé JD. Traitement de l'hépatite aiguë C. Gastroentérologie clinique & biologique 2002; 26: 32-7.